Get the Stockscreener App
13.57
6.93%
-1.01
After Hours:
13.59
0.02
+0.15%
Kalvista Pharmaceuticals Inc stock is traded at $13.57, with a volume of 1.89M.
It is down -6.93% in the last 24 hours and up +18.93% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$14.58
Open:
$14.6
24h Volume:
1.89M
Relative Volume:
1.72
Market Cap:
$677.87M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-3.6775
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
-12.79%
1M Performance:
+18.93%
6M Performance:
+52.99%
1Y Performance:
-8.25%
1-Day Range:
$13.55
$14.78
1-Week Range:
$13.55
$15.97
52-Week Range:
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
13.57 | 728.33M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency - Insider Monkey
What institutional investors are buying KalVista Pharmaceuticals Inc. stockUnlock daily market insights for better trades - jammulinksnews.com
What is the dividend policy of KalVista Pharmaceuticals Inc. stockBreakthrough investment results - jammulinksnews.com
What are analysts’ price targets for KalVista Pharmaceuticals Inc. in the next 12 monthsUnlock high-yield investment opportunities - jammulinksnews.com
KalVista Pharmaceuticals Faces Downgrade Due to Shrinking Market and Oral Competitor Threat - AInvest
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) - Seeking Alpha
Kalvista Pharmaceuticals shares rise 1.17% after-hours following positive CHMP opinion for sebetralstat. - AInvest
EMA’s CHMP adopts five orphans - BioCentury
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
What analysts say about KalVista Pharmaceuticals Inc. stockFree Daily Trading Room Entry - Autocar Professional
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
European regulator recommends approval of first oral HAE treatment - Investing.com India
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
What drives KalVista Pharmaceuticals Inc. stock priceFree Daily Trading Room Entry - PrintWeekIndia
US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India
(KALV) Proactive Strategies - news.stocktradersdaily.com
JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa
JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace
KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener
KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener
KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha
UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada
(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
MHRA approves Ekterly to treat HAE - The Pharma Letter
KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):